• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Puretech’s Gele­sis flunks the FDA’s key mea­sure of suc­cess for weight loss treat­ments

8 years ago
R&D

Vi­su­al­ize: What would these 11 biotech com­pa­nies look like with­out im­mi­grants?

8 years ago
R&D
Biotech Voices

Al­ler­gan caps a bad day with news the FDA has kicked back a sup­ple­men­tal ap­pli­ca­tion for cariprazine

8 years ago
Pharma

FDA spurns J&J's trou­bled rheuma­toid arthri­tis drug sirukum­ab

8 years ago
Pharma

How En­ter­prise cus­tomers can get End­points News in­to their Slack

8 years ago
Publisher's note

Ab­b­Vie part­ners on an Op­di­vo com­bo study with Bris­tol-My­ers; In­ter­cept tum­bles on FDA warn­ing

8 years ago
News Briefing

GSK vets Wit­ty and Slaoui find new roles in biotech as the great mi­gra­tion con­tin­ues

8 years ago
Peer Review

Two years on, Al­ler­gan’s $1.7B NASH drug still looks weak — at best

8 years ago
R&D

Or­biMed, RA Cap­i­tal back a $26M raise for Realm’s two mid-stage drugs

8 years ago
Financing
Startups

Ab­b­Vie’s top ex­ecs paint a rosy pic of the mega-block­buster fu­ture loom­ing for Hu­mi­ra and PhI­II drugs

8 years ago
R&D
Pharma

House com­mit­tee wants to know a lot more about the cy­ber­at­tack that dam­aged Mer­ck

8 years ago
Pharma

Ver­sar­tis shares ham­mered by a PhI­II flop as growth hor­mone flunks key test

8 years ago
R&D

Sanofi, NIH cre­ate a three-pronged an­ti­body to tar­get HIV; Akari soars on PhI­II plans; Juno plots planned $225M raise

8 years ago
News Briefing

A Chi­na biotech uni­corn scores big with $150M-plus IPO on Nas­daq, stock rock­ets up

8 years ago
Financing
China

Nes­tle plans to ax hun­dreds of R&D staffers, shut­ter big der­ma­tol­ogy cam­pus

8 years ago
R&D
Pharma

With help from J&J, up­start Proven­tion lands rights to two mid-stage IBD drugs and shoots for PhII

8 years ago
Startups
Pharma

Chris Garabe­di­an's Xon­toge­ny shep­herds its first biotech through a $10M start­up round

8 years ago
People
Financing

Want to start fix­ing the gen­der di­ver­si­ty prob­lem in your biotech com­pa­ny? Put down the sil­ver bul­let

8 years ago
R&D
Pharma

Af­ter set­tling with the SEC, biotech VC Steven Bur­rill now faces up to 30 years for fraud, tax eva­sion charges

8 years ago
People

FDA's Janet Wood­cock: the clin­i­cal tri­als sys­tem is 'bro­ken'

8 years ago
Pharma

Ar­cus scores $305M re­gion­al de­vel­op­ment pact with Tai­ho; Shire, Sh­iono­gi tout PhI­II AD­HD study

8 years ago
News Briefing

An­gry Pfiz­er ac­cus­es J&J of vi­o­lat­ing an­titrust laws in safe­guard­ing a megablock­buster fran­chise

8 years ago
Pharma

Sanofi's Elias Zer­houni says his R&D group is ready to stand alone — but big M&A and part­ner­ships still loom large

8 years ago
Deals

Light­stone crew adds a $250M Fund II with plans to back biotech star­tups

8 years ago
Financing
First page Previous page 1093109410951096109710981099 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times